{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:47:37Z","timestamp":1792514857652,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28308-8","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:59:07Z","timestamp":1767023947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose response of nafamostat mesylate for anticoagulation monitoring in pediatric critical care during continuous venovenous hemodiafiltration"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0516-0846","authenticated-orcid":false,"given":"Sujin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-7452","authenticated-orcid":false,"given":"Jongyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-9644","authenticated-orcid":false,"given":"Bongjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"28308_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease","year":"2012","unstructured":"Kidney Disease. Improving global outcomes acute kidney injury Work, G. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Supplements. 2, 1\u2013138. https:\/\/doi.org\/10.1038\/kisup.2012.1 (2012).","journal-title":"Kidney Int. Supplements"},{"key":"28308_CR2","doi-asserted-by":"crossref","unstructured":"Assadi, F. & Ghane Sharbaf, F. Pediatric Continuous Renal Replacement Therapy: Principles and Practice (Springer, 2016).","DOI":"10.1007\/978-3-319-26202-4"},{"key":"28308_CR3","doi-asserted-by":"publisher","first-page":"e2246901","DOI":"10.1001\/jamanetworkopen.2022.46901","volume":"5","author":"M Daverio","year":"2022","unstructured":"Daverio, M. et al. Continuous kidney replacement therapy practices in pediatric intensive care units across Europe. JAMA Netw. Open. 5, e2246901. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.46901 (2022).","journal-title":"JAMA Netw. Open."},{"key":"28308_CR4","doi-asserted-by":"publisher","unstructured":"Schetz, M. Anticoagulation in continuous renal replacement therapy. Contrib. Nephrol. 283\u2013303. https:\/\/doi.org\/10.1159\/000060097 (2001).","DOI":"10.1159\/000060097"},{"key":"28308_CR5","doi-asserted-by":"publisher","unstructured":"Oh, H. S. et al. Pharmacokinetics of Nafamostat, a potent Serine protease Inhibitor, by a novel LC-MS\/MS analysis. Molecules 27 https:\/\/doi.org\/10.3390\/molecules27061881 (2022).","DOI":"10.3390\/molecules27061881"},{"key":"28308_CR6","doi-asserted-by":"publisher","first-page":"20176","DOI":"10.1038\/s41598-023-47644-1","volume":"13","author":"TOC Dos Santos","year":"2023","unstructured":"Dos Santos, T. O. C. et al. Hypercitratemia is a mortality predictor among patients on continuous venovenous hemodiafiltration and regional citrate anticoagulation. Sci. Rep. 13, 20176. https:\/\/doi.org\/10.1038\/s41598-023-47644-1 (2023).","journal-title":"Sci. Rep."},{"key":"28308_CR7","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41598-022-05867-8","volume":"12","author":"P Thanapongsatorn","year":"2022","unstructured":"Thanapongsatorn, P. et al. Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT. Sci. Rep. 12, 1815. https:\/\/doi.org\/10.1038\/s41598-022-05867-8 (2022).","journal-title":"Sci. Rep."},{"key":"28308_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000189371","volume":"74","author":"H Maruyama","year":"1996","unstructured":"Maruyama, H., Miyakawa, Y., Gejyo, F. & Arakawa, M. Anaphylactoid reaction induced by Nafamostat mesilate in a Hemodialysis patient. Nephron 74, 468\u2013469. https:\/\/doi.org\/10.1159\/000189371 (1996).","journal-title":"Nephron"},{"key":"28308_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000215139","volume":"15","author":"Y Hitomi","year":"1985","unstructured":"Hitomi, Y., Ikari, N. & Fujii, S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15, 164\u2013168. https:\/\/doi.org\/10.1159\/000215139 (1985).","journal-title":"Haemostasis"},{"key":"28308_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","volume":"661","author":"S Fujii","year":"1981","unstructured":"Fujii, S. & Hitomi, Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, Kallikrein and trypsin. Biochim. Biophys. Acta. 661, 342\u2013345. https:\/\/doi.org\/10.1016\/0005-2744(81)90023-1 (1981).","journal-title":"Biochim. Biophys. Acta"},{"key":"28308_CR11","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00467-022-05567-5","volume":"37","author":"A Deep","year":"2022","unstructured":"Deep, A. Anticoagulation strategies in continuous kidney replacement therapy - does one size fit all? Pediatr. Nephrol. 37, 2525\u20132529. https:\/\/doi.org\/10.1007\/s00467-022-05567-5 (2022).","journal-title":"Pediatr. Nephrol."},{"key":"28308_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","volume":"29","author":"D Liu","year":"2024","unstructured":"Liu, D. et al. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study. Eur. J. Med. Res. 29, 72. https:\/\/doi.org\/10.1186\/s40001-024-01660-7 (2024).","journal-title":"Eur. J. Med. Res."},{"key":"28308_CR13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/0886022x.2022.2105233","volume":"44","author":"Y Lin","year":"2022","unstructured":"Lin, Y. et al. Efficacy and safety of Nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis. Ren. Fail. 44, 1263\u20131279. https:\/\/doi.org\/10.1080\/0886022x.2022.2105233 (2022).","journal-title":"Ren. Fail."},{"key":"28308_CR14","first-page":"E30","volume":"63","author":"Y Miyatake","year":"2017","unstructured":"Miyatake, Y., Makino, S., Kubota, K., Egi, M. & Mizobuchi, S. Association between Intra-Circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using Nafamostat mesilate: a retrospective pilot observational study. Kobe J. Med. Sci. 63, E30\u2013E36 (2017).","journal-title":"Kobe J. Med. Sci."},{"key":"28308_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/BF03018658","volume":"50","author":"H Iwama","year":"2003","unstructured":"Iwama, H., Watanabe, K. & Obara, S. In vitro relationship between the blood Nafamostat concentration and activated coagulation time. Can. J. Anaesth. 50, 621\u2013622. https:\/\/doi.org\/10.1007\/BF03018658 (2003).","journal-title":"Can. J. Anaesth."},{"key":"28308_CR16","unstructured":"Hemochron 401 Coagulation Analyzer, (2024). https:\/\/www.somatechnology.com\/coagulation-analyzers\/hemochron-401"},{"key":"28308_CR17","unstructured":"ITC Product Catalog \u2013 Coagulation Tubes, (2011). https:\/\/catachemlatinamerica.com\/wp-content\/uploads\/2011\/08\/ITC-Product-Catalog.pdf"},{"key":"28308_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3346\/jkms.2011.26.7.945","volume":"26","author":"SJ Han","year":"2011","unstructured":"Han, S. J. et al. Use of Nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J. Korean Med. Sci. 26, 945\u2013950. https:\/\/doi.org\/10.3346\/jkms.2011.26.7.945 (2011).","journal-title":"J. Korean Med. Sci."},{"key":"28308_CR19","unstructured":"R: A language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, Austria, 2023)."},{"key":"28308_CR20","unstructured":"Foundation, P. S. Python: A Dynamic, Open Source Programming Language. (2023)."},{"key":"28308_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","volume":"585","author":"CR Harris","year":"2020","unstructured":"Harris, C. R., Millman, K. J., van der Walt, S. J. & Gommers, R. Array programming with numpy. Nature 585, 357\u2013362 (2020).","journal-title":"Nature"},{"key":"28308_CR22","doi-asserted-by":"crossref","unstructured":"McKinney, W. Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in Science Conference, 51\u201356 (2010).","DOI":"10.25080\/Majora-92bf1922-00a"},{"key":"28308_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. & Matplotlib A 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"28308_CR24","unstructured":"Taylor, J. Patsy: Describing Statistical Models in Python, (2023). https:\/\/patsy.readthedocs.io\/"},{"key":"28308_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P., Gommers, R., Oliphant, T. E. & Haberland, M. SciPy 1.0: fundamental algorithms for scientific computing in python. Nat. Methods. 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"28308_CR26","unstructured":"Waskom, M. Seaborn: Statistical Data Visualization, (2023). https:\/\/seaborn.pydata.org\/"},{"key":"28308_CR27","doi-asserted-by":"crossref","unstructured":"Seabold, S., Perktold, J. & Statsmodels Econometric and Statistical Modeling with Python. Proceedings of the 9th Python in Science Conference, 92\u201396 (2010).","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"28308_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jointm.2024.02.003","volume":"4","author":"Q He","year":"2024","unstructured":"He, Q., Wei, Y., Qian, Y. & Zhong, M. Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: potential targets for Nafamostat mesilate. J. Intensive Med. 4, 453\u2013467. https:\/\/doi.org\/10.1016\/j.jointm.2024.02.003 (2024).","journal-title":"J. Intensive Med."},{"key":"28308_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4266\/acc.2021.01312","volume":"37","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. et al. The role of Nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation. Acute Crit. Care. 37, 177\u2013184. https:\/\/doi.org\/10.4266\/acc.2021.01312 (2022).","journal-title":"Acute Crit. Care"},{"key":"28308_CR30","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1111\/aor.14276","volume":"46","author":"F Sanfilippo","year":"2022","unstructured":"Sanfilippo, F. et al. Use of Nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review. Artif. Organs. 46, 2371\u20132381. https:\/\/doi.org\/10.1111\/aor.14276 (2022).","journal-title":"Artif. Organs"},{"key":"28308_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5301\/IJAO.5000191","volume":"36","author":"SD Hwang","year":"2013","unstructured":"Hwang, S. D., Hyun, Y. K., Moon, S. J., Lee, S. C. & Yoon, S. Y. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int. J. Artif. Organs. 36, 208\u2013216. https:\/\/doi.org\/10.5301\/IJAO.5000191 (2013).","journal-title":"Int. J. Artif. Organs"},{"key":"28308_CR32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1440-1746.2009.05801.x","volume":"24","author":"T Cakir","year":"2009","unstructured":"Cakir, T., Cingi, A. & Ye\u011fen, C. Coagulation dynamics and platelet functions in obstructive jaundiced patients. J. Gastroenterol. Hepatol. 24, 748\u2013751. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05801.x (2009).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"28308_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.rgmxen.2023.08.008","volume":"89","author":"I Aiza-Haddad","year":"2024","unstructured":"Aiza-Haddad, I. et al. Guidelines for the management of coagulation disorders in patients with cirrhosis. Rev. Gastroenterol. Mex (Engl Ed). 89, 144\u2013162. https:\/\/doi.org\/10.1016\/j.rgmxen.2023.08.008 (2024).","journal-title":"Rev. Gastroenterol. Mex (Engl Ed)"},{"key":"28308_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/0886022X.2011.647293","volume":"34","author":"NN Baek","year":"2012","unstructured":"Baek, N. N. et al. The role of Nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren. Fail. 34, 279\u2013285. https:\/\/doi.org\/10.3109\/0886022X.2011.647293 (2012).","journal-title":"Ren. Fail."},{"key":"28308_CR35","doi-asserted-by":"publisher","first-page":"e108737","DOI":"10.1371\/journal.pone.0108737","volume":"9","author":"YK Lee","year":"2014","unstructured":"Lee, Y. K., Lee, H. W., Choi, K. H. & Kim, B. S. Ability of Nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One. 9, e108737. https:\/\/doi.org\/10.1371\/journal.pone.0108737 (2014).","journal-title":"PLoS One"},{"key":"28308_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000102081","volume":"156","author":"I Baldwin","year":"2007","unstructured":"Baldwin, I. Factors affecting circuit patency and filter \u2018life\u2019. Contrib. Nephrol. 156, 178\u2013184. https:\/\/doi.org\/10.1159\/000102081 (2007).","journal-title":"Contrib. Nephrol."},{"key":"28308_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-017-0445-5","volume":"18","author":"M Brain","year":"2017","unstructured":"Brain, M., Winson, E., Roodenburg, O. & McNeil, J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 18, 69. https:\/\/doi.org\/10.1186\/s12882-017-0445-5 (2017).","journal-title":"BMC Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28308-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28308-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28308-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:14:56Z","timestamp":1777115696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28308-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28308"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28308-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6632150\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44847"}}